These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cell-based approach for treatment of corneal endothelial dysfunction. Okumura N; Kinoshita S; Koizumi N Cornea; 2014 Nov; 33 Suppl 11():S37-41. PubMed ID: 25188790 [TBL] [Abstract][Full Text] [Related]
4. Current development of alternative treatments for endothelial decompensation: Cell-based therapy. Rodríguez-Fernández S; Piñeiro-Ramil M; Castro-Viñuelas R; Sanjurjo-Rodríguez C; Álvarez-Portela M; Fuentes-Boquete IM; Rendal-Vázquez E; M Díaz-Prado S Exp Eye Res; 2021 Jun; 207():108560. PubMed ID: 33811914 [TBL] [Abstract][Full Text] [Related]
5. Experimental models of corneal endothelial cell therapy and translational challenges to clinical practice. Rolev K; Coussons P; King L; Rajan M Exp Eye Res; 2019 Nov; 188():107794. PubMed ID: 31518569 [TBL] [Abstract][Full Text] [Related]
6. Feasibility of cell-based therapy combined with descemetorhexis for treating Fuchs endothelial corneal dystrophy in rabbit model. Okumura N; Matsumoto D; Fukui Y; Teramoto M; Imai H; Kurosawa T; Shimada T; Kruse F; Schlötzer-Schrehardt U; Kinoshita S; Koizumi N PLoS One; 2018; 13(1):e0191306. PubMed ID: 29338061 [TBL] [Abstract][Full Text] [Related]
10. A short-term in vivo experimental model for Fuchs endothelial corneal dystrophy. Haydari MN; Perron MC; Laprise S; Roy O; Cameron JD; Proulx S; Brunette I Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6343-54. PubMed ID: 22915029 [TBL] [Abstract][Full Text] [Related]
11. [Fuchs endothelial corneal dystrophy and trinucleotide repeat expansion in TCF4--implications for diagnostics and therapy]. Oziębło D; Szaflik JP; Ołdak M Klin Oczna; 2015; 117(3):200-3. PubMed ID: 26999947 [TBL] [Abstract][Full Text] [Related]
12. Corneal Endothelial-like Cells Derived from Induced Pluripotent Stem Cells for Cell Therapy. Ng XY; Peh GSL; Yam GH; Tay HG; Mehta JS Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569804 [TBL] [Abstract][Full Text] [Related]
13. Delivery of Antisense Oligonucleotides to the Cornea. Chau VQ; Hu J; Gong X; Hulleman JD; Ufret-Vincenty RL; Rigo F; Prakash TP; Corey DR; Mootha VV Nucleic Acid Ther; 2020 Aug; 30(4):207-214. PubMed ID: 32202944 [TBL] [Abstract][Full Text] [Related]
15. Regulatory Compliant Tissue-Engineered Human Corneal Endothelial Grafts Restore Corneal Function of Rabbits with Bullous Keratopathy. Peh GSL; Ang HP; Lwin CN; Adnan K; George BL; Seah XY; Lin SJ; Bhogal M; Liu YC; Tan DT; Mehta JS Sci Rep; 2017 Oct; 7(1):14149. PubMed ID: 29074873 [TBL] [Abstract][Full Text] [Related]
16. Five-Year Follow-up of First 11 Patients Undergoing Injection of Cultured Corneal Endothelial Cells for Corneal Endothelial Failure. Numa K; Imai K; Ueno M; Kitazawa K; Tanaka H; Bush JD; Teramukai S; Okumura N; Koizumi N; Hamuro J; Sotozono C; Kinoshita S Ophthalmology; 2021 Apr; 128(4):504-514. PubMed ID: 32898516 [TBL] [Abstract][Full Text] [Related]
17. In Vitro Topographical Model of Fuchs Dystrophy for Evaluation of Corneal Endothelial Cell Monolayer Formation. Rizwan M; Peh GS; Adnan K; Naso SL; Mendez AR; Mehta JS; Yim EK Adv Healthc Mater; 2016 Nov; 5(22):2896-2910. PubMed ID: 27701826 [TBL] [Abstract][Full Text] [Related]
18. Modified corneal collagen crosslinking reduces corneal oedema and diurnal visual fluctuations in Fuchs dystrophy. Hafezi F; Dejica P; Majo F Br J Ophthalmol; 2010 May; 94(5):660-1. PubMed ID: 20447971 [No Abstract] [Full Text] [Related]